Peer-Reviewed Publication
JCO Precis Oncol2026;10(9):e2600095.September 1, 2026Journal Article
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.
Thomas W P Friedl1, Peter A Fasching2, Andreas D Hartkopf1,3, Hans Tesch4, Ralf Lorenz5, Georg Heinrich6, Jens-Uwe Blohmer7, Tanja Fehm8, Volkmar Mueller9, Andreas Schneeweiss10, Matthias W Beckmann2, Matthias Ruebner2, Nadia Harbeck11, Klaus Pantel12,13, Derek Dustin14, Mingyang Cai14, Brigitte Rack1, Wolfgang Janni1
1Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
2Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
3Department of Gynecology and Obstetrics, Tübingen University Hospital, Tübingen, Germany.
4Department of Oncology, Onkologie Bethanien, Frankfurt, Germany.
5Gynecologic Practice Dr Lorenz, N. Hecker, Dr Kreiss-Sender, Braunschweig, Germany.
6Department of Gynecologic Oncology, Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany.
7Department of Gynecology and Breast Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
8Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Heinrich-Heine University, Düsseldorf, Germany.
9Department of Gynecology, University Hamburg-Eppendorf, Hamburg, Germany.
10Division of Gynecologic Oncology and German Cancer Research Center, National Center for Tumor Diseases, Heidelberg, Germany.
11Department of Obstetrics and Gynecology and CCC Munich, Breast Center, LMU University Hospital, Munich, Germany.
12Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
13European Liquid Biopsy Society (ELBS), Hamburg, Germany.
14Guardant Health, Palo Alto, CA.
Abstract
PURPOSE: Circulating tumor DNA (ctDNA) may serve as a biomarker to facilitate early identification of asymptomatic distant tumor spread in patients with breast cancer. The primary objective of this study was to assess clinical validity and prognostic value of post-treatment tissue-free ctDNA detection by evaluating its sensitivity for distant metastatic recurrence and its association with long-ter…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans